Deals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
BioMarin PharmaceuticalNASDAQ: BMRN

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has entered into an exclusive worldwide (excluding Korea) license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to co‑develop and…

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
AIHisun Pharmaceutical

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Aosaikang Licenses Adlai Nortye's Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
Adlai NortyeAosaikang Pharmaceutical

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
Greater Bay AreaNeuroGen Pharma

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
AbbVieCancer

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Show More